Compare Global X Cybersecurity (BUG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs Gilead Sciences, Inc. — how do they compare? Global X Cybersecurity trades at $42.48, while Gilead Sciences, Inc. trades at $129.81 (market cap $163.14B). The key difference: Gilead Sciences, Inc. pays a 2.5% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| BUG | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $155.80 |
52-Week Low | $23.30 | $108.22 |
Market Cap | — | $163.14B |
Enterprise Value | — | $177.67B |
Dividend Yield | — | 2.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
